Physician profile
Mary E Torres
NPI 1508977927
$3,170.84
in general payments reported to CMS, 2019-2025
36 companies · $497 in 2025
The $497 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $482 · 2020: $403 · 2021: $780 · 2022: $469 · 2023: $313 · 2024: $226 · 2025: $497.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $852 · Education: $185.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $851.67 |
| Education | $184.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $468.86 | 2019-2024 | Lo Loestrin Fe |
| Applied Medical Resources Corporation | $389.43 | 2021 | |
| Mayne Pharma Commercial LLC | $304.35 | 2021-2025 | |
| Astellas Pharma US INC | $266.13 | 2023-2025 | Myrbetriq, Veozah |
| Pfizer INC. | $204.04 | 2019-2025 | |
| Daiichi Sankyo INC. | $154.74 | 2019-2022 | |
| Hologic Sales and Service, LLC | $117.60 | 2019-2025 | Aptima, Thinprep 2000 Processor |
| Avion Pharmaceuticals | $115.06 | 2019-2020 | |
| Therapeuticsmd, INC. | $114.50 | 2019-2022 | |
| Millicent US INC | $93.11 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Bayer Healthcare Pharmaceuticals INC. | $89.33 | 2019-2020 | |
| Exeltis, USA INC. | $68.17 | 2021-2025 | Slynd |
| Lundbeck LLC | $66.87 | 2019-2020 | |
| Exact Sciences Corporation | $66.17 | 2023-2025 | Cologuard Collection Kit |
| Lupin INC. | $53.59 | 2019-2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $50.75 | 2021-2022 | |
| Allergan, INC. | $45.15 | 2019-2020 | |
| Agile Therapeutics, INC. | $44.89 | 2021-2023 | Twirla |
| Merck Sharp & Dohme LLC | $44.26 | 2019-2024 | Gardasil 9, Gardasil |
| Mylan Pharmaceuticals INC. | $39.11 | 2021 | |
| Sumitomo Pharma America, INC. | $37.56 | 2024-2025 | Gemtesa |
| Myovant Sciences INC. | $34.98 | 2021-2022 | |
| Endo USA, INC. | $34.38 | 2024-2025 | Xiaflex, Aveed |
| Biohaven Pharmaceutical Holding Company Ltd. | $33.95 | 2022 | |
| Medtronic, INC. | $33.00 | 2024-2025 | Interstim |
| Duchesnay USA Incorporated | $25.16 | 2019 | |
| Amag Pharmaceuticals, INC. | $23.76 | 2019-2020 | |
| Olympus America INC. | $21.50 | 2019 | |
| Novo Nordisk INC | $21.40 | 2019 | |
| Organon LLC | $20.60 | 2022-2023 | Nexplanon |
| Scynexis, INC. | $18.49 | 2022 | |
| Ferring Pharmaceuticals INC. | $17.44 | 2025 | Adstiladrin |
| Mission Pharmacal Company | $17.17 | 2019 | |
| Laborie Medical Technologies Corp. | $15.19 | 2025 | Optilume Bph Drug Coated Balloon Catheter |
| Coloplast Corp | $13.94 | 2025 | |
| Boston Scientific Corporation | $6.21 | 2025 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Torres listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.